Opendata, web and dolomites

PDX-PC SIGNED

Elucidation of tumour cell plasticity mechanisms associated to treatment in metastatic prostate cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PDX-PC project word cloud

Explore the words cloud of the PDX-PC project. It provides you a very rough idea of what is the project "PDX-PC" about.

preserve    resistance    pdx    benefit    fact    elucidate    guide    patient    clinicians    therapy    liquid    plasticity    choices    analysed    discover    cell    costly    despite    models    undergoing    led    setting    free    predictive    causing    durable    vivo    circulating    few    clinical    multidisciplinary    mortality    patients    approved    multiple    metastatic    tumour    responsible    burden    xenografts    rate    signatures    men    cancer    mechanisms    evolution    prevent    initially    highlights    reprogram    options    pc    treatments    sequences    subsequent    increment    worldwide    accounts    themselves    declined    initial    curative    clinic    heterogeneity    rna    blocked    tissues    sequencing    outcomes    prostate    survive    biomarkers    absence    biopsy    malignancies    disease    cells    decisions    bioinformatics    treatment    responding    economic    ups    regimens    individualized    molecular    therapies    validated    unnecessary    dna    follow    last    therapeutic    optimal    prevalence   

Project "PDX-PC" data sheet

The following table provides information about the project.

Coordinator
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER 

Organization address
address: CALLE ROSSELLO 149 PUERTA BJS
city: BARCELONA
postcode: 8036
website: http://www.idibaps.org/en_index.html

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 166˙202 €
 EC max contribution 166˙202 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-GF
 Starting year 2019
 Duration (year-month-day) from 2019-09-16   to  2021-09-15

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) coordinator 166˙202.00
2    MONASH UNIVERSITY AU (VICTORIA) partner 0.00

Map

 Project objective

Prostate cancer (PC) is among the top five leading malignancies causing cancer mortality worldwide. Increased prevalence and declined mortality rate have led to an increment in follow-ups with a significant rise in the economic burden. In the last few years, several new options for metastatic disease have been approved leading to clinicians to have multiple choices of therapy sequences. However, not all patients initially respond and most of them eventually develop resistance. The ability of tumour cells to reprogram themselves and survive despite the blocked targets (tumour cell plasticity) may accounts for the absence of durable responses. In addition, the fact that initial treatments may affect the potential benefit of subsequent treatments highlights the need to discover predictive biomarkers for optimal treatment selection, allowing early changes in treatment for non-responding patients. This multidisciplinary project aims to elucidate the molecular mechanisms responsible for tumour cell plasticity associated to treatment response in metastatic PC. Patient-derived xenografts (PDX) in vivo models will be used, since they preserve molecular heterogeneity and therapeutic response observed in the clinic. They will be treated under different regimens. Tumour tissues will be analysed by RNA sequencing before and after treatment. Bioinformatics analysis will be used to establish molecular signatures of treatment response that will be validated in liquid biopsy (circulating tumour cells and cell free DNA) from metastatic PC patients undergoing different treatments. PDX-PC will provide a better understanding of the molecular evolution of the disease that will contribute to design more specific and individualized treatments. In the setting of non-curative therapy, the implementation of such molecular findings at clinical practice may help to guide treatment decisions, improve outcomes, and prevent unnecessary side effects and costly therapies in men with metastatic PC.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PDX-PC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PDX-PC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

LYSOKIN (2020)

Architecture and regulation of PI3KC2β lipid kinase complex for nutrient signaling at the lysosome

Read More  

OSeaIce (2019)

Two-way interactions between ocean heat transport and Arctic sea ice

Read More  

EcoSpy (2018)

Leveraging the potential of historical spy satellite photography for ecology and conservation

Read More